References
- Swain MG, Lai MY, Shiffman ML, et al. A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin. Gastroenterology 2010;139(5):1593-601
- Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82
- Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31(Suppl 2):61-80
- Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31(Suppl 2):30-60
- Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57(4):1333-42
- Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45(4):529-38
- Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144(10):705-14
- Hahne SJ, Veldhuijzen IK, Wiessing L, et al. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis 2013;13:181
- Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360(18):1839-50
- Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364(25):2405-16
- McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360(18):1827-38
- McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362(14):1292-303
- Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364(25):2417-28
- Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1207-17
- Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195-206
- Maasoumy B, Port K, Markova AA, et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One 2013;8(2):e55285
- EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60(2):392-420
- AASLD, IDSA, IAS–USA. Recommendations for testing, managing, and treating hepatitis C. Available from: www.hcvguidelines.org [Last accessed 9 April 2014]
- Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. N Engl J Med 2013;368(20):1878-87
- Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014;34(Suppl 1):69-78
- Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370(16):1483-93
- Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370(20):1889-98
- Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370(20):1879-88
- Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med 2014;370(17):1594-603
- Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without Ribavirin for HCV. N Engl J Med 2014. [Epub ahead of print]
- Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis c with cirrhosis. N Engl J Med 2014. [Epub ahead of print]
- Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370(17):1604-14
- Ray SC, Thomas DL, Hepatitis C. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett’s principles and practice of infectious diseases. Elsevier; Philadelphia, USA: 2010. p. 2157-85
- Lim PJ, Chatterji U, Cordek D, et al. Correlation between NS5A dimerization and hepatitis C virus replication. J Biol Chem 2012;287(36):30861-73
- Guedj J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci USA 2013;110(10):3991-6
- Fridell RA, Qiu D, Valera L, et al. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol 2011;85(14):7312-20
- Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465(7294):96-100
- Belema M, Nguyen VN, Bachand C, et al. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem 2014;57(5):2013-32
- Nettles RE, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011;54(6):1956-65
- Ke R, Loverdo C, Qi H, et al. Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrob Chemother 2014;69(3):724-7
- Bifano M, Sevinsky H, Hwang C, et al. Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate. Antivir Ther 2013. [Epub ahead of print]
- Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 2013;18(7):931-40
- Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461(7262):399-401
- Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010;51(4):1122-6
- Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366(3):216-24
- Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012;12(9):671-7
- Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012;55(3):742-8
- Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013;58(4):655-62
- Izumi N, Yokosuka O, Kawada N, et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antivir Ther 2014. [Epub ahead of print]
- Suzuki F, Toyota J, Ikeda K, et al. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection. Antivir Ther 2014. [Epub ahead of print]
- Lok AS, Gardiner DF, Hezode C, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014;60(3):490-9
- Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370(3):211-21
- Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01629732&Search=Search
- Sheridan C. Calamitous HCV trial casts shadow over nucleoside drugs. Nat Biotechnol 2012;30(11):1015-16
- Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection. Gastroenterology 2014;146(2):420-9
- UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01979939&Search=Search
- Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011;54(6):1924-35
- Wang C, Sun JH, O’Boyle DR 2nd, et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother 2013;57(5):2054-65
- Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013;58(4):646-54
- Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014. [Epub ahead of print]
- Jacobson I, Dimitrova D, Hughes EA, et al. 1203 Safety profile of daclatasvir in combination with peginterferon alfa and ribavirin in 1100 patients with chronic HCV infection treated in phase 2 studies. J Hepatol 2013;58:S489
- Bristol-Meyers Squibb Press Release. Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for All-Oral Daclatasvir Dual Investigational Regimen for Chronic Hepatitis C. Available from: http://news.bms.com/press-release/bristol-myers-squibb-receives-us-fda-breakthrough-therapy-designation-all-oral-daclata [Last accessed 9 April 2014]
- Bristol-Meyers Squibb Press Release. Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency. Available from: http://news.bms.com/press-release/daclatasvir-marketing-authorization-application-treatment-chronic-hepatitis-c-validate [Last accessed 9 April 2014]
- Fontana RJ, Hughes EA, Appelman H, et al. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012;18(9):1053-9
- Fontana RJ, Hughes EA, Bifano M, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013;13(6):1601-5
- Volk ML. Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother 2010;65(7):1327-9
- Weis SE, Slocum PC, Blais FX, et al. The Effect of Directly Observed Therapy on the Rates of Drug Resistance and Relapse in Tuberculosis. N Engl J Med 1994;330(17):1179-84
- Hill A, Khoo S, Fortunak J, et al. Minimum costs for producing hepatitis c direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis 2014;58(7):928-36
- Study of BMS-790052 Add-On to Standard of Care in Treatment Naive Subjects. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01125189&Search=Search
- Study in Genotype 2/3 Subjects With Chronic Hepatitis C. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01257204&Search=Search
- Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01629732&Search=Search
- Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01309932&Search=Search
- Study of Daclatasvir and TMC435 for Subjects With Genotype 1 Chronic Hepatitis C. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01628692&Search=Search
- Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01425970&Search=Search
- A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01842451&Search=Search
- Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01795911&Search=Search
- Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01866930&Search=Search
- Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Not Been Treated With Standard of Care. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01359644&Search=Search
- Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01725542&Search=Search
- Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01170962&Search=Search
- UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01973049&Search=Search
- Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV. Available from: www.clinicaltrials.gov/ct2/results?term=NCT02032901&Search=Search
- A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01718145&Search=Search
- Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01995266&Search=Search
- Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01581203&Search=Search
- Study Comparing BMS-790052 (Daclatasvir) to Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Untreated Hepatitis C Patients. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01492426&Search=Search
- Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01616524&Search=Search
- Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01718158&Search=Search
- BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01389323&Search=Search
- Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01448044&Search=Search
- Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01573351&Search=Search
- Phase III HIV/HCV Co-Infection Daclatasvir (DCV)+ Sofosbuvir (SOF. Available from: www.clinicaltrials.gov/ct2/results?term=NCT02032888&Search=Search
- Phase III Daclatasvir, Sofosbuvir, and Ribavirin in cirrhotic subjects and subjects post-liver transplant. Available from: www.clinicaltrials.gov/ct2/results?term=NCT02032875&Search=Search
- Safety and efficacy study of BMS-790052 plus peg-interferon Alfa 2a and ribavirin in untreated hepatitis c patients coinfected with HIV virus. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01471574&Search=Search
- Safety and efficacy study in subjects with chronic HCV and underlying hemophilia. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01741545&Search=Search